Novo Nordisk A/S has warned of a troubling decline in sales projected between 5% to 13% for 2026, driven by fierce competition and U.S. pricing pressures. Following the grim forecast, the company's stock plummeted over 21% in just a week, erasing more than $50 billion in market value. Despite robust early demand for its Wegovy pill, Novo Nordisk faces increasing challenges from competitors like Hims & Hers and pricing regulations that threaten its profitability.
“Rough sales outlook sinking shares of $NVO. BMO's Evan David Seigerman weighs in on the move and what it means for the obesity drug market.”
“Denmark’s largest pension fund sees no buy-the-dip opportunity in Novo Nordisk A/S’s shares after the drugmaker warned that sales will fall in 2026, underscoring how investors on its home turf have little confidence in the stock.”
“"I think $NVO would fare better if it never got into this business," says @MizuhoAmericas' Jared Holz. He reacts to the growing divergence in the GLP-1 drugmakers.”
“Novo Nordisk A/S (NYSE:NVO) increased its advertising spending for its GLP-1 medication in the U.S. In the first nine months of 2025, the company allocated nearly $500 million to promote Wegovy and Ozempic.”
“Novo Nordisk provided pretty dismal guidance for 2026 when it reported 2025 earnings. There are obviously a lot of moving parts, but the big picture numbers are that sales and earnings are both expected to decline between 5% and 13%.”
“the company saw more customers buy its new GLP-1 pill than it had originally expected. After just four weeks, the company had 170,000 patients using the pill version of its weight loss drug.”
“the early success of the pill indicates that, eventually, volume could offset the GLP-1 pricing hit that will take shape in 2026. Given the CEO's comments about 2026, that seems to be the company's internal expectation.”
“Additionally, some retirees enrolled in Medicare Part D plans will see their GLP-1 weight-loss drug prices capped at $50 per month. This change is due to an agreement between the Trump administration and GLP-1 drug makers Eli Lilly and Novo Nordisk.”
“On February 4, Novo Nordisk A/S warned that “unprecedented” pricing pressure would cause sales and profits to fall for the first time in years. According to the company, the pricing pressure will affect its weight-loss drug Wegovy and related diabetes treatments.”
“It said the pressure comes from increasing competition and aggressive negotiations by healthcare payers, which are pushing drug prices lower.”
“On February 5, Novo Nordisk A/S (NYSE:NVO) said it would take legal action against Hims & Hers after the telehealth company announced plans to sell compounded versions of Wegovy at $49 per month.”
“Novo Nordisk has taken legal action against telehealth platform Hims & Hers after it launched a compounded, non branded version of Wegovy, Novo Nordisk's weight loss pill. Following the lawsuit threat and increased scrutiny, Hims & Hers pulled the product, while the FDA moved against unapproved compounded GLP 1 copycat drugs.”
